Globus Medical Appoints Keith Pfeil As CEO And Reports Strong Q2 Sales Growth Driven By Nevro Acquisition

Globus Medical, Inc., a leader in musculoskeletal technology, announced a leadership transition effective July 18, 2025. Keith Pfeil, who currently serves as Executive Vice President, Chief Operating Officer, and Chief Financial Officer, has been appointed as the new President and Chief Executive Officer. This change follows the resignation of current CEO Daniel Scavilla, who is leaving the company to pursue another professional opportunity. In addition, Kyle Kline, currently Senior Vice President of Finance, has been promoted to Chief Financial Officer.

“It has been an honor to lead Globus Medical and be part of this exceptional team,” said Dan Scavilla. “As the Company continues to move forward, I have made the decision to step down to pursue another opportunity. I look forward to watching the Company’s continued success as Keith leads Globus into its next chapter and know that he will drive meaningful impact to the Company as it moves ahead. I’m proud to have been part of Globus.”

“We are excited to appoint Keith Pfeil as our next President and Chief Executive Officer. Keith brings a sharp strategic mindset and a results-orientated leadership style with a clear understanding of how to drive performance across an organization. His manner and approach demonstrate strong cultural alignment with the Globus philosophy, and we look forward to him leading us as Globus continues to execute its strategy of becoming the pre-eminent musculoskeletal technology company in the world. Keith began his career with Globus in 2019 as Senior Vice President and Chief Financial Officer. In 2024, he was named Executive Vice President, Chief Operating Officer and Chief Financial Officer. Keith’s leadership has been vital to executing our strategy over the past six years and he is ideally positioned to expand that influence across the organization as CEO,” said David C. Paul, Globus Medical Founder and Executive Chairman. 

“On behalf of the Board and all the employees of Globus, I want to thank Dan for his leadership and commitment to Globus over the past 10 years. Dan has helped us with our vision of transitioning Globus from an implant and instrument provider to a musculoskeletal technology and solutions provider. We are grateful for his contributions and wish him continued success in his next chapter,” commented Mr. Paul. 

Alongside the leadership changes, Globus Medical has released preliminary sales results for the second quarter ending June 30, 2025. The company expects total Q2 sales to reach approximately $745.3 million, marking an 18.4% increase compared to the same quarter in 2024. This growth includes contributions from the recent acquisition of Nevro, Inc., which has significantly boosted overall revenue.

“I’m deeply grateful to David and the Board for this opportunity and want to thank Dan for his mentorship and partnership throughout my journey thus far at Globus. I’ve had the opportunity to grow with this team over the past 6 years, and I am excited to carry forward our strong culture of purpose, innovation and teamwork that will meaningfully impact the lives of patients as we move ahead” commented Keith Pfeil, President and Chief Executive Officer.

“I’m thrilled to welcome Kyle Kline to our executive leadership team as the next CFO of Globus. After spending almost 10 years with Deloitte, Kyle joined Globus in 2017 as the Assistant Controller and has continuously taken on increased financial responsibility over his eight-year career. He and I have worked closely together, and he’s been a valued and trusted partner of mine. The combination of his integrity, passion and knowledge of our business makes him the right choice to lead Globus as its next CFO,” commented Mr. Pfeil. 

Excluding Nevro’s contribution, the base business revenue is expected to be around $650.8 million — a 3.3% increase year-over-year on a reported basis. On a day-adjusted basis, base business growth stands at 4.8% versus Q2 2024. These figures suggest stable organic growth, even as the company undergoes key leadership transitions and expands through strategic acquisitions.

“Our second quarter results demonstrated a significant improvement over Q1, led by our US Spine business, which grew approximately 7.4 percent on a day-adjusted basis compared to the prior year quarter, as well as notable sequential improvement in Enabling Technology sales. Our US Spine business had strong, consistent momentum throughout Q2, delivering its highest quarterly revenue result since the 2023 merger with NuVasive. Looking ahead, we seek to continue this trend, while continuing to convert our Enabling Technologies pipeline” commented Keith Pfeil, President and CEO.